STOCKHOLM: Episurf Medical AB said Tuesday it has signed letters of intent to acquire four real estate portfolios with a combined property value of about 2.6 billion Swedish kronor, marking a major expansion into property management.
The portfolios consist of roughly 90 light industrial, residential and community properties across Sweden, with a total lettable area of approximately 150,000 square meters. They generate annual net operating income of about 165 million kronor, representing an average yield of 6.4%, the company said.
Preliminary signing and completion are expected in the second and third quarters of 2026.
Episurf plans to finance the acquisitions through a mix of assumed bank loans, new Class B shares issued at 0.055 kronor per share, convertible notes, and short-term vendor-financed loans. The convertible notes have a term of up to 24 months, with conversion prices ranging from 0.065 to 0.085 kronor per share.
“The letters of intent are a clear testament to the interest in the platform we are building,” CEO Jens Andersson said. “We look forward to completing the acquisitions.”
The company, best known for its Episealer individualized joint implants, is pivoting toward building a cash flow-generating real estate platform focused on Nordic properties. Episurf’s headquarters are in Stockholm.
EDITOR’S COMMENTARY: This is a striking strategic pivot. Episurf Medical is best known for orthopedic implants, yet here it is acquiring nearly 2.6 billion kronor worth of warehouses and apartments. The financing — heavy on equity dilution and convertible notes at very low single-digit subscription prices — raises questions about whether existing medtech shareholders signed up for a property play. Andersson calls it a “platform,” but investors may wonder: is this diversification or a shift in identity? The real story will be whether the medical technology business remains a priority or becomes an afterthought.